Drug information of Risankizumab


Drug group:

Risankizumab is used to treat moderate to severe plaque psoriasis in adults

Mechanism of effect

Risankizumab acts to prevent the release of pro-inflammatory cytokines and chemokines that often lead to inflammatory skin symptoms, such as redness, pain, and plaques.  Risankizumab binds with a high affinity to the p19 subunit of human interleukin 23 (IL-23) cytokine 2, thereby preventing its action on the IL-23 receptor. IL-23 is a cytokine released in the human body that is involved in inflammatory and immune processes, especially in peripheral tissues


No formal studies examining pharmacodynamic properties have been completed with risankizumab , however, this drug is expected to relieve symptoms of psoriasis by targeting interleukin 23 (IL-23) and preventing the initiation of the

inflammatory cascade that is implicated in psoriasis



Vdss: 11.2 L


Degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG

Time to Peak

3 to 14 days

Half-Life Elimination

~28 days

Drug indications

This drug is for the treatment of moderate-to-severe plaque psoriasis in adults who are eligible to receive systemic therapy or phototherapy based on their disease process


Plaque psoriasis, moderate to severe: SubQ: Two consecutive injections (75 mg each) for a total dose of 150 mg at weeks 0, 4, and then every 12 weeks thereafter.

Drug contraindications

There are no contraindications listed in the manufacturer's labeling

Side effects

  • Body aches or pain
  • chest pain
  • chills
  • confusion
  • cough
  • difficulty in breathing
  • dizziness
  • ear congestion
  • fast heartbeat
  • fever
  • headache
  • increase in bone pain
  • itching, pain, redness, swelling, tenderness, or warmth on the skin
  • lightheadedness
  • loss of voice
  • sore throat
unusual tiredness or weakness


Infections: Risankizumab may increase the risk of infections; upper respiratory tract and tinea infections have occurred more frequently. Consider the risks versus benefits prior to treatment initiation in patients with a history of chronic or recurrent infection; treatment should not be initiated in patients with clinically important active infections until it is resolved or treated..

• Tuberculosis: Patients should be evaluated for tuberculosis (TB) infection prior to initiating therapy. Do not administer to patients with an active TB infection. Treatment for latent TB should be administered prior to administering risankizumab. Monitor closely for signs/symptoms of active TB during and after risankizumab treatment.

Points of recommendation

Common cold symptoms

  • Loss of strength and energy
  • Injection site irritation
  • Headache


  • Flu-like symptoms
  • Shortness of breath

Weight loss

  • Warm, red, or painful skin or sores

Pregnancy level

US FDA pregnancy category: Not assigned.

Ask a Pharmacist

User's questions
    No comments yet.